title: Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards.
abstract: This article describes the simultaneous Biacore analysis of human anti-human antibodies (HAHAs) with respect to the binding region and the isotype by a combination of 11 single measurements per sample. The multiplexing single assay setup made efficient use of the four parallel flow cells on one biosensor chip by immobilization of full-length antibody and its constant (Fc) and antigen binding (Fab) fragments for differential binding analysis of anti-drug antibodies (ADAs). Thereby, a complete time-specific immunogenicity profile (intensity, isotype, specificity, and kinetics) of a patient could be obtained by assessing the response patterns of serially collected samples analyzed in a single measurement run. The use of functionally active standard conjugates allowed control of the assay performance throughout the whole procedure. The positive control standard conjugates mimicking polyclonal human ADAs of different isotypes were obtained by conjugating polyclonal rabbit antibodies against the therapeutic antibody to human immunoglobulin (Ig) M, IgG, or IgE. In this article, the qualification of the assay is demonstrated and the application of the methodology to six representative rheumatoid arthritis patients treated with the therapeutic humanized IgG1 antibody tocilizumab (anti-IL-6R) is shown to illustrate the versatility of the assay. The presented method allows one to differentiate specific ADAs from drug-unspecific responses (e.g., rheumatoid factors). In addition, the method can be used to discriminate between isotype responses of the IgG, IgM, and IgE types and, thereby, allows one to describe the time course of specific ADA formation and its disappearance on the single patient level.
authors.affiliation: Pharma Research Penzberg, Department of Bioanalytics, Roche Diagnostics, 82377 Penzberg, Germany. kay-gunnar.stubenrauch@roche.com
authors.forename: Kay
authors.initials: K
authors.lastname: Stubenrauch
authors.forename: Uwe
authors.initials: U
authors.lastname: Wessels
authors.forename: Rudolf
authors.initials: R
authors.lastname: Vogel
authors.forename: Julia
authors.initials: J
authors.lastname: Schleypen
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000097:blood* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000628:therapy; D001666:Binding Sites, Antibody; D006801:Humans; D007118:Immunoassay / Q000379:methods; D007132:Immunoglobulin Isotypes / Q000097:blood* / Q000276:immunology; D007167:Immunotherapy; D011817:Rabbits; D012680:Sensitivity and Specificity; D020349:Surface Plasmon Resonance / Q000379:methods*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007132:Immunoglobulin Isotypes; C502936:tocilizumab